Elliott Management Corp., the hedge fund founded by billionaire Paul Singer, has built a stake in Sky Plc as shareholders prepare to vote on 21st Century Fox Inc.’s 11.7-billion...
Keep Reading →
January 29 - Hedge Funds, Insider Trading - Comments
What are the best healthcare stocks to invest in? Baupost Group was founded in 1982 by Harvard Professor William Poorvu and partners Howard Stevenson, Jordan Baruch and Isaac ...
Keep Reading →
December 15 - Hedge Funds, News - Comments
Hedge fund managers like David Einhorn, Dan Loeb, or Carl Icahn became billionaires through reaping large profits for their investors, which is why piggybacking their stock picks...
Keep Reading →
December 11 - Hedge Funds, News - Comments
The fourth quarter of this year is set to be a big one in the biotech space, with a number of key development slated across October, November and December.
Keep Reading →
October 20 - News, Stock Analysis - Comments
Among the stocks registering significant moves are Whiting Petroleum Corp (NYSE:WLL), Ionis Pharmaceuticals Inc (NASDAQ:IONS), TOP SHIPS Inc (NASDAQ:TOPS), MeetMe Inc (NASDAQ:...
Keep Reading →
August 1 - Earnings Report, News - Comments
Even though oil continues to plummet, the market is rebounding on Tuesday, with all major U.S stock indexes trading up.
Keep Reading →
March 29 - Market Movers, News - Comments
A high majority of hedge fund managers delivered a terrible performance in 2015 and widely-known value investor Seth Klarman was no exception.
Keep Reading →
February 15 - Hedge Fund Analysis, Hedge Funds, News - Comments
Like everyone else, elite investors make mistakes.
Keep Reading →
December 5 - Hedge Funds, News - Comments
On a day when Valeant Pharmaceuticals Intl Inc (NYSE:VRX) is deep in the red following the release of its third quarter earnings, four other biotech stocks are making strong gains...
Keep Reading →
October 19 - Market Movers, News - Comments
Key bank earnings and economic data have reinvigorated the U.S stock market today.
Keep Reading →
October 15 - Market Movers, News - Comments
Some investors think billionaire Seth Klarman is the next Warren Buffett. Given that Klarman's $31 billion fund, Baupost Group, has achieved average annual returns of 17% a...
Keep Reading →
October 14 - News - Comments
Amid a broader market sell-off, several biotechnology stocks have surged in today’s trading session, although the industry overall has declined with the NASDAQ Biotech Index...
Keep Reading →
September 24 - Hedge Funds, Market Movers, News - Comments
The Baupost Group is a Boston-based hedge fund founded and operated by billionaire Seth Klarman.
Keep Reading →
May 22 - Hedge Funds, News - Comments
Billionaire Seth Klarman is a notorious investor who despite his uncoventional approaches always managed to achieve high returns.
Keep Reading →
March 15 - Hedge Funds, News - Comments
Seth Klarman is bullish on Keryx Biopharmaceuticals (NASDAQ:KERX) and his fund, Baupost Group, has recently surged its position in the company.
Keep Reading →
October 10 - Hedge Funds, News - Comments
On Wednesday, May 14th, Seth Klarman’s Baupost Group, presented its Form 13F Filing for the first quarter of 2014 at the U.S. Securities and Exchange Commission.
Keep Reading →
May 15 - Hedge Funds - Comments
In the 21st century investor’s toolkit, there are dozens of indicators shareholders can use to analyze publicly traded companies.
Keep Reading →
September 17 - News - Comments
There were definitely some good parts in what Keryx Biopharmaceuticals (NASDAQ:KERX) had to say at this week's Stifel Nicolaus Weisel Healthcare Conference in Boston.
Keep Reading →
September 15 - News - Comments
To the average investor, there are tons of methods market participants can use to track publicly traded companies.
Keep Reading →
September 13 - News - Comments
In the financial world, there are dozens of indicators investors can use to track publicly traded companies. Two of the best are hedge fund and insider trading movement.
Keep Reading →
September 4 - News - Comments
Drugs fail their clinical trials for all kinds of reasons. Sometimes, it's related to efficacy; sometimes, it's safety related.
Keep Reading →
August 30 - News - Comments
In the eyes of many investors, hedge funds are seen as useless, outdated investment tools of a forgotten age.
Keep Reading →
August 30 - News - Comments
Keryx Biopharmaceuticals (NASDAQ:KERX) announced its second-quarter results before the market opened on Thursday.
Keep Reading →
August 1 - News - Comments
Today, let's look at the California State Teachers' Retirement System ("CalSTRS"), a major pension fund that's celebrating its 100th anniversary in 2013.
Keep Reading →
July 29 - News - Comments
Large healthcare companies are facing revenue declines due to expiring patents.
Keep Reading →
July 25 - News - Comments
The U.S. is the largest market of biotechnology products in the world.
Keep Reading →
July 18 - News - Comments
Only a handful of stocks have gained 200% in 2013, and five of those stocks are in the biotechnology industry.
Keep Reading →
July 12 - News - Comments
At the moment, there are plenty of metrics shareholders can use to watch Mr. Market. A pair of the best are hedge fund and insider trading activity.
Keep Reading →
June 17 - News - Comments
Kythera Biopharmaceuticals Inc (NASDAQ:KYTH) was in 10 hedge funds' portfolio at the end of March.
Keep Reading →
June 14 - News - Comments
Astex Pharmaceuticals, Inc. (NASDAQ:ASTX) was in 16 hedge funds' portfolio at the end of March.
Keep Reading →
June 12 - News - Comments
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) was in 16 hedge funds' portfolio at the end of the first quarter of 2013.
Keep Reading →
June 6 - News - Comments
According to most shareholders, hedge funds are seen as unimportant, outdated investment vehicles of years past.
Keep Reading →
June 4 - News - Comments
In today’s marketplace, there are many gauges investors can use to track publicly traded companies. A couple of the best are hedge fund and insider trading sentiment.
Keep Reading →
June 3 - News - Comments
Shaw is known as a math wizard, and a quantitative investing pioneer. His firm is reportedly extremely selective, hiring less than 1% of applicants -- and Amazon.com, Inc.
Keep Reading →
May 31 - Hedge Funds - Comments
Huge fortunes are won and lost in the world of biotech nearly every week. For those new to this world, it can appear both alluring and scary.
Keep Reading →
May 22 - News - Comments
Editor's Note: Related tickers: Caterpillar Inc.
Keep Reading →
April 22 - News - Comments
Keryx Biopharmaceuticals (NASDAQ:KERX) was in 6 hedge funds' portfolio at the end of December.
Keep Reading →
April 18 - News - Comments
Exchange-traded funds offer a convenient way to invest in sectors or niches that interest you.
Keep Reading →
April 16 - News - Comments
To most stock holders, hedge funds are seen as unimportant, old financial vehicles of the past.
Keep Reading →
April 4 - News - Comments
They don't have any products on the market. They have little or no revenue. Earnings? Nada. Many people are betting that they will fail.
Keep Reading →
April 4 - News - Comments
Today, let's look at Tudor Investment, founded in 1980 by Paul Tudor Jones and featuring the flagship Tudor BVI fund.
Keep Reading →
April 1 - News - Comments
Today, let's look at Passport Capital, which was founded by John Burbank in 2000 and known for combining macroeconomic analysis and fundamental research.
Keep Reading →
March 20 - Hedge Funds - Comments
Young, upstart pharmaceutical and biotech companies do one thing that almost no other industry does. They go years without generating any revenue.
Keep Reading →
March 5 - News - Comments
Recently, Keryx Biopharmaceuticals (NASDAQ:KERX) achieved a new milestone as the company declared remarkable results from its Phase 3 trials of Zerenex.
Keep Reading →
February 25 - News - Comments
Clinical trial 101 says if a trial passes all of its primary endpoints it's successful. If it doesn't, it's not.
Keep Reading →
February 14 - News - Comments
Keryx Biopharmaceuticals (NASDAQ:KERX)’s latest kidney drug called Zerenex is a game changer for the company after achieving positive results from its long-term Phase 3 study...
Keep Reading →
February 11 - News - Comments
OraSure Technologies, Inc. (NASDAQ:OSUR) announced its fourth-quarter results after the market closed on Wednesday.
Keep Reading →
February 9 - News - Comments
The market had two ways to view Friday's employment numbers.
Keep Reading →
February 5 - News - Comments
Young, upstart pharmaceutical and biotech companies do one thing that almost no other industry does. They go years without generating any revenue.
Keep Reading →
February 2 - News - Comments
